| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
3 |
| Employees |
16 |
| Revenues (TTM) (Millions $) |
2 |
| Net Income (TTM) (Millions $) |
4 |
| Cash Flow (TTM) (Millions $) |
-6 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Seelos Therapeutics Inc. is a biopharmaceutical company focused on developing novel treatments for central nervous system disorders. The company utilizes innovative technologies and scientific expertise to identify and develop potential therapies for diseases such as Parkinson's disease, amyotrophic lateral sclerosis (ALS), and other neuropsychiatric disorders.
Seelos Therapeutics aims to address unmet medical needs by advancing promising drug candidates through clinical trials and regulatory approval processes. Their pipeline includes both early-stage and late-stage compounds that target different aspects of these disorders, ranging from neuroprotection to symptom management.
The company is committed to translating scientific discoveries into viable treatment options for patients. They collaborate with researchers, clinicians, and patient advocacy groups to ensure their therapies are developed with the patient's needs in mind.
Overall, Seelos Therapeutics Inc. strives to make a meaningful impact on the lives of individuals suffering from neurodegenerative and neuropsychiatric disorders by bringing innovative and effective therapies to market.
Company Address: 300 Park Avenue New York 10022 NY
Company Phone Number: 293-2100 Stock Exchange / Ticker: NASDAQ SEEL
|
%
0.19%